Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

BACKGROUND: Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute myeloid leukemia (r/r AML), but identification of this subset remains difficult. METHODS: To search for biomarkers o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Woonbok, Kelly, Andrew D., Kropf, Patricia, Fung, Henry, Jelinek, Jaroslav, Su, Xiang Yao, Roboz, Gail J., Kantarjian, Hagop M., Azab, Mohammad, Issa, Jean-Pierre J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647096/
https://www.ncbi.nlm.nih.gov/pubmed/31331399
http://dx.doi.org/10.1186/s13148-019-0704-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647096/
https://www.ncbi.nlm.nih.gov/pubmed/31331399
http://dx.doi.org/10.1186/s13148-019-0704-3

Ejemplares similares